Research and development CRO list: "2020 China CRO Enterprise 20" grandly released!

Guide: CRO enterprises take root in the research and development system, by the increasingly powerful new drug system demand.
the reform of domestic pharmaceutical industry policy has accelerated since 2015, especially after China joined ICH in 2017, domestic pharmaceutical enterprises have accelerated the transformation and upgrading from generic drugs to generic combination.
domestic and foreign package services demand side is accelerating expansion, the domestic pharmaceutical market innovation and upgrading dividend is gradually emerging.
some traditional offshoring enterprises began to attach importance to the expansion of domestic business, onshore outsourcing business in the overall business composition of the beginning of the proportion also has an upward trend.
cro, as one of the most important components of the research and development service system for innovative drugs, refers to an academic or commercial scientific institution that provides specialized services to pharmaceutical companies and research and development institutions in the drug development process through contract.
part of the research and development of new drug projects, so that the risk of new drug research and development can be effectively dispersed throughout the industrial chain.
this way, pharmaceutical companies can reduce fixed costs, reduce costs, but also effectively shorten the research and development cycle of new drugs, improve overall research and development efficiency, and gain valuable time for the commercialization of innovative drugs.
research shows that the scale of the CRO industry is positively related to the research and development costs of pharmaceutical companies: as long as the pharmaceutical companies' research and development investment is still growing rapidly and CRO penetration is still increasing, the industry still has a lot of room for growth.
According to Shanxi Securities Research Institute statistics, in 2019, the 11 listed companies in medical services operating income growth rate of 25.21%, net profit growth of 22.26%, net profit growth of 34.41%, medical service price reform policy plus code, consistent evaluation and pharmaceutical innovation CRO demand growth, driven by the industry to maintain a high business climate.
profitability, gross margin increased by 1.09 percentage points year-on-year and net profit margin remained stable, while sales expense rate, management expense rate and financial expense rate remained basically stable.
September 10, 2020, the 2020 China Pharmaceutical and Health Industry Development Conference and the 4th China Pharmaceutical Research and Development Innovation Summit (PDI) announced the 2020 China Research and Development CRO Enterprise Top 20 (hereinafter referred to as the "Research and Development CRO List").
as far as the CRO industry environment is concerned, the domestic is still "many", "small" and "scatter" as the main pattern, in 2019 this aspect has not changed much, the overall number of enterprises is still showing an upward trend.
pyramid effect has been emphasized again, according to the relevant reports, the current annual revenue of more than 100 million CRO enterprises are still a minority, only about 6% (more than 30), about 94% of CRO enterprises revenue of less than 100 million yuan.
Looking at the world, due to the long-term technology accumulation of head CRO enterprises brought about by the technical advantages and customer stickiness, as well as mergers and acquisitions within the industry, the global CRO industry concentration continues to improve, according to the Institute of Forward Industry statistics, the world's top ten CRO enterprise market share of more than 60%.
domestic enterprises are not so much developing rapidly, more may still be "survival in the seams".
especially in the field of clinical CRO, there is still a lot of room for improvement of domestic industry leaders.
the domestic clinical trial service leader - Tagg Pharma this "Research and Development CRO list", the top of the list by Hangzhou Tyger Pharmaceutical Technology Co., Ltd. won (hereinafter referred to as "Tiger Pharmaceuticals"), a strong strength worthy of clinical trial service leader status.
achieved operating income of RMB2.803 billion in 2019, up 21.85 percent YoY, and net profit attributable to shareholders of listed companies was RMB841 million, up 78.24 percent YoY.
source: Tagg Pharmaceuticals Annual Report Source: Tiger Pharmaceuticals Annual Report 2012-2019, Tiger Pharmaceuticals revenue and net profit increased year by year, 2019 net profit growth rate was even higher; During the year, tag pharma's new contract amounted to 4.231 billion yuan (-27.9%), the cumulative contract to be executed was 5,011 million yuan (-36.1%), with abundant orders in hand, guaranteed future revenue growth, and a solid leading position in the clinical CRO field.
investment in research and development, Tiger Pharma invested 124 million yuan in research and development in 2019, an increase of 40.91 percent year-on-year.
research and development staff has also increased steadily, from 42 to 468 in 2019.
on the one hand to increase investment in research and development, on the other hand, the introduction of talent, capital and holding of the two core elements, Tig Pharmaceuticals has both.
's research and development achievements in 2019 mainly include: providing the whole process of clinical trial services for the research and development of Chongqing Yongren heart implanted left achhimate assist system.
in-depth cooperation in a number of clinical research projects on new drugs for Ze-Yu Pharmaceuticals.
provides the whole process service for the clinical trial declaration of the 1 class of targeted anti-cancer drug TY-302 capsules of Zhejiang Tongyuan Kang Pharmaceuticals.
provides full-process technical services, including product registration, clinical studies, etc., to RSR's Water Channel Protein Antibody (AQP4/Ab) test kits.
provides a full-process SMO service for the clinical study of GlaxoSmithKline's (GSK) long-acting triple inhalation preparation, Full Re-Music.
(Source: Tyger Pharmaceuticals Annual Report) At the same time, the proportion of Tyger Pharma's business in China has gradually increased in recent years, reaching 56.7% in 2019, which has largely consolidated its position as a leader in clinical trial services in China.
's preclinical safety evaluation leader - Zhao Yanxin pharmaceutical this time ranked third in the "Research and Development CRO list" is known as the "clinical pre-clinical safety evaluation leader" of Beijing Zhaoying New Drug Research Center Co., Ltd. (hereinafter referred to as "Zhao Yan new drug").
2019, Zhao yanxin pharmaceutical realized operating income of 639 million yuan, up 56.40% YoY, realized net profit of 178 million yuan, up 64.64% YoY, and realized net profit of 155 million yuan, up 71.41% YoY, with very good results.
Zhaoyian new drug as a drug non-clinical safety evaluation services-based domestic preclinical CRO enterprises, but also China's first through the United States FDA / GLP examination of enterprises, the main business mainly refers to preclinical toxicology research, including safety pharmacology tests, reproductive toxicity tests, genetic toxicity tests, cancer-causing trials.
new drug data and achievements, in 2019, Zhao yan new drugs are also a point of contention, in hand orders surged to 1.04 billion, an increase of 30% yoY.
also completed more than 230 large-molecule innovative drugs IND work, was approved more than 60, and in the ophthalmology and other fields made major breakthroughs.
contracts signed by the Chinese government have been growing at a high rate, up more than 50% from 2018, and Zhao Yan's new drug has a strong explosive power, both now and in the future.
on the other hand, since 2014, the gross profit margin and net profit margin of zhao yanxin drug sales have also maintained a solid growth trend.
as profitability improved, the debt ratio fell from 64.78 per cent to 41.65 per cent, reducing financial pressures.
even with sales costs rising by 88.24 per cent, the company is operating well, mainly due to rapid growth in labor compensation and business volume, but management and financial expenses remain reasonably low.
Photo Source: Annual Report of Enterprises, Research Report, Public Data Collation In addition, the majority of the current revenue of Zhao yanxin drug from the domestic enterprise cooperation business (2019 Zhao Yanxin drug from the domestic business reached 92%), on the one hand reflects its domestic roots, domestic leading ideas and position, on the other hand, can also foresee its overseas market profit margins, over time, will also rise.
Strong rookie - Kanglong into the "Research and Development CRO List" runner-up enterprises for the second largest CRO enterprise giant, often compared with the drug Mingkangde Kangcheng (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as "Kanglong into").
fact, if you look deeply at the difference between the two, their areas of expertise are actually different.
2019, Kanglonghua achieved full-year operating income of 3.757 billion yuan, home-to-home net profit of 547 million yuan and non-attributed net profit of 550 million yuan, up 29.2%, 64.3% and 58.2% year-on-year, respectively, with results basically in line with expectations.
Photo Source: Kanglong into enterprise research, public data collation at the same time, Kanglong into 2015-2019 performance growth rate is obvious, although the growth rate in 2016 slightly decreased, but its quarterly revenue growth is around 30%, the overall industry position gradually consolidated.
will continue to focus on increasing infrastructure construction and expanding scale and capacity in 2019.
Drug Safety Evaluation Center will expand its 3,500-square-meter animal experimental facility in 2019, and the Shanghai branch will begin operations.
, the lab services business added 595 employees, up 16.06 percent year-on-year to 4,301.
Photo Source: Kanglong into enterprise research, public data collation, and more notable "laboratory services" as the cornerstone of the company Kanglong into a cornerstone business, in 2019 to achieve revenue of 2.380 billion yuan, an increase of 25.52 percent year-on-year.
CMC business benefited from business synergy, but also maintained high-speed growth, to achieve revenue of 902 million yuan (-39.60%), clinical research services revenue of 456 million yuan, an increase of 31.30% YoY, business stickiness intensity increased at the same time, it can be seen that the cornerstone business "leader" role can not be ignored.
At the same time, in 2019, Kanglongcheng's research and development expenses amounted to 62.8715 million yuan, an increase of nearly 100% over 2018, focusing on the DNA coding compound library, new synthetic chemical technology (including photochemistry, mobile chemistry, bio-catalysis and other new reaction technology) and other heavy areas, its core competitiveness has been qualitatively improved.
as far as Kanglong into the whole, the 2019 big action constantly, to a large extent, shows kanglong into an end, make every effort, a hundred feet closer to the next step, leading a solid industry leader position.
conclusion that although CRO industry is a new industry that has only developed in China in the past 20 years, it shows no less courage and prospect than most traditional enterprises.
In particular, in the new pharmaceutical environment, new policy guidance, new drug research and development needs, the CRO industry has been deeply rooted in the research and development system, by the increasingly powerful new drug system needs, the two work together, twin symbigion.
.